What is SGP's Value Score?

SpyGlass Pharma, Inc. - Common Stock (SGP) has a StockPik Value Score of 35 out of 100 — a low score, indicating weak value characteristics. The Value Score is a composite ranking built from P/E ratio, P/B ratio, Graham Number, ROE, gross margin, debt-to-equity, current ratio, and Piotroski F-Score, calculated from SEC EDGAR annual filing data.

What is SGP's Piotroski F-Score?

SpyGlass Pharma, Inc. - Common Stock (SGP) has a Piotroski F-Score of 3 out of 9 — a weak score indicating financial deterioration across multiple criteria. The F-Score assesses nine binary financial criteria across profitability, leverage, and operating efficiency. A score of 7–9 indicates a financially improving company; a score of 0–3 is a warning sign.

What is SGP's Piotroski F-Score?

SGP's Piotroski F-Score is 3 out of 9, indicating weak financial health and possible deterioration. The Piotroski F-Score evaluates nine criteria across profitability, leverage, and operating efficiency. Scores of 7 or above are considered strong; 3 or below indicate financial weakness.

Is SGP (SpyGlass Pharma, Inc. - Common Stock) undervalued?

SGP scores 35/100 on StockPik's Value Score.

What sector is SpyGlass Pharma, Inc. - Common Stock (SGP) in?

SpyGlass Pharma, Inc. - Common Stock (SGP) is in the Healthcare sector, specifically in the Surgical & Medical Instruments & Apparatus industry. Compare it against other Healthcare stocks by Value Score, P/E ratio, and Piotroski F-Score on StockPik.

Back to Screener

SpyGlass Pharma, Inc. - Common Stock (SGP)

NASDAQ Small Cap

Healthcare › Surgical & Medical Instruments & Apparatus

$24.27

Market Cap: $811M

Data as of Dec 31, 2025

Price History

Mar 12, 2026 — May 15, 2026

Investment Snapshot

P/B of 3.24 — trading above book value
Piotroski F-Score 3/9 — signs of financial weakness
Loss-making — negative ROE of -15.9%

SpyGlass Pharma, Inc. - Common Stock (SGP) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NASDAQ , with a market capitalisation of $811 million . Key value metrics: P/B ratio 3.24, Piotroski F-Score 3 out of 9 .

Value Score

out of 100

Try PRO Free — See Full Breakdown

Key Metrics

P/E Ratio

—

P/B Ratio

3.24

EPS

$-1.19

Div. Yield

—

PEG Ratio

—

P/S Ratio

—

EV/EBITDA

—

ROE

—

ROA

—

Gross Margin

—

Op. Margin

—

Net Margin

—

Debt/Equity

—

Current Ratio

—

Unlock 19 More Metrics — 7 Days Free

Data sourced from SEC EDGAR and Polygon.io. Methodology. View more Healthcare stocks →

SpyGlass Pharma, Inc. - Common Stock — Fundamental Analysis Summary

On financial health, SGP shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -15.9% (sector average: -20.6%).

StockPik's composite Value Score for SGP is 35/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

SGP shows earnings declining at 37%.

Top Value Stocks in Healthcare

Symbol	Name	Price	P/E	Score
EMBC	Embecta Corp. - Common Stock	$3.90	2.1	100
HCM	HUTCHMED (China) Limited - American Depositary Shares	$13.31	5.1	100
GMAB	Genmab A/S - American Depositary Shares	$27.06	1.8	100
CGEN	Compugen Ltd. - Ordinary Shares	$2.71	7.3	100
INVA	Innoviva, Inc. - Common Stock	$22.89	5.8	100

Browse all Healthcare value stocks →

How is the Value Score calculated?

Read our full methodology →

What is the Piotroski F-Score?

The 9-point financial health score explained, with worked examples →

SGN — SIGNING DAY SPORTS, INC.

SPAR Group, Inc. - Common Stock — SGRP